Material Event (Form 8-K)

On July 7, 2026, Galera Therapeutics, Inc., a Delaware corporation (the "Company"), announced that its board of directors approved a one-for-two hundred (1:200) reverse stock split ("Reverse Stock Split") of the Company's common stock, par value $0.001 ("Common Stock").

The Reverse Stock Split is expected to become effective on July 12, 2026 as of 11:59 p.m. Eastern Time (the "Effective Time"), with shares to begin trading on a split-adjusted basis at market open on July 13, 2026. In connection with the Reverse Stock Split, every two hundred shares of Common Stock issued and outstanding as of the Effective Time will be automatically converted into one share of Common Stock. No fractional shares will be issued in connection with the Reverse Stock Split; the Company's stockholders will be entitled to receive the cash value equal to the fraction to which the stockholder would otherwise be entitled, multiplied by the closing price of Common Stock, as reported on the OTCQB Market, on the last trading day prior to the effective date of the Reverse Stock Split.

In addition, the Reverse Stock Split will effect a reduction in the number of shares of Common Stock (i) available for issuance under the Company's 2019 Equity Incentive Plan and 2023 Employment Inducement Award Plan, and (ii) issuable upon the exercise of stock options outstanding immediately prior to the effectiveness of the Reverse Stock Split. To reflect the Reverse Stock Split, there will also be a corresponding increase in the exercise price per share applicable to outstanding stock options.

The Reverse Stock Split will also effect a proportionate reduction in the number of shares of Common Stock issuable upon the exercise of the Company's outstanding warrants, with a corresponding adjustment to the exercise price per share applicable to each such warrant.

The aforementioned adjustments will occur automatically upon effectiveness of the Reverse Stock Split.